Document Detail


Botulinum toxin therapy in the ovalbumin-sensitized rat.
MedLine Citation:
PMID:  17713354     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of this study was to determine whether intranasal administration of botulinum toxin type A (BTX-A) could relieve the typical symptoms of allergic rhinitis (AR) and alter substance P (SP)- and vasoactive intestinal peptide (VIP)-immunoreactive (IR) expression in nasal mucosa of AR animals sensitized with ovalbumin (OVA). METHODS: AR was induced by intraperitoneal injection of OVA followed by its repeated intranasal instillation in female Wistar rats. Some AR animals were intranasally treated with a cotton strip containing BTX-A (10 U per nostril) for 1 h. After BTX-A treatment, OVA was repeatedly instilled in AR and AR + BTX-A groups every 2 days for 10 days. Subsequently, nasal symptoms were evaluated, and nasal secretions collected. Finally, the nasal mucosae of all animals were prepared for histological and immunohistochemical assessment. RESULTS: BTX-A administration alleviated typical AR symptoms including rhinorrhea, nasal itching and sneezing, and subsequent intranasal repeated challenge with OVA did not trigger AR symptoms. After BTX-A treatment, inflammatory histological characteristics within the nasal mucosa of AR animals were absent, but atrophy of serous glands was observed. BTX-A decreased dense SP-IR and VIP-IR cells and fibers within and beneath the epithelium, around blood vessels and close to serous glands in AR animals. CONCLUSION: Local BTX-A treatment is an effective method to reduce AR symptoms. BTX-A decreased the excessive SP-IR and VIP-IR expression induced by OVA. Therefore, BTX-A may affect the nasal mucosa via the suppression of neuropeptides, playing a major role in autonomous mucosal innervation in the pathophysiology of AR.
Authors:
Wei-Dong Wen; Fang Yuan; Jian-Lin Wang; Yi-Ping Hou
Related Documents :
6596684 - Pgf2 alpha mediated cytoprotection: a reassessment.
8141304 - Phosphoramidon attenuates big endothelin-1-induced vasoconstriction in canine stomach.
15914574 - Increased duodenal iron uptake and transfer in a rat model of chronic hypoxia is accomp...
10480484 - Gastric prostacyclin (pgi2) prevents stress-induced gastric mucosal injury in rats prim...
8941504 - Importance of airway blood flow on particle clearance from the lung.
8970524 - Temporal changes in function and regional glucose uptake within stunned porcine myocard...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-08-21
Journal Detail:
Title:  Neuroimmunomodulation     Volume:  14     ISSN:  1021-7401     ISO Abbreviation:  Neuroimmunomodulation     Publication Date:  2007  
Date Detail:
Created Date:  2007-09-20     Completed Date:  2007-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9422763     Medline TA:  Neuroimmunomodulation     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  78-83     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2007 S. Karger AG, Basel.
Affiliation:
School of Life Science, Lanzhou University, Lanzhou, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intranasal
Allergens / immunology
Animals
Botulinum Toxin Type A / administration & dosage*
Female
Immunohistochemistry
Nasal Mucosa / drug effects*
Ovalbumin / immunology
Rats
Rats, Wistar
Rhinitis, Allergic, Seasonal / chemically induced,  drug therapy*
Substance P / drug effects
Vasoactive Intestinal Peptide / drug effects
Chemical
Reg. No./Substance:
0/Allergens; 0/Botulinum Toxin Type A; 33507-63-0/Substance P; 37221-79-7/Vasoactive Intestinal Peptide; 9006-59-1/Ovalbumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of sleep deprivation on the corticosterone secretion in an experimental model of autoimmune d...
Next Document:  Impact of gender and menstrual cycle phase on plasma cytokine concentrations.